Comparative Pharmacology
Head-to-head clinical analysis: ATRIDOX versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRIDOX versus VIBRAMYCIN.
ATRIDOX vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATRIDOX (doxycycline hyclate) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases (MMPs) and reducing cytokine production.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
50 mg subgingival controlled-release insert applied by dental professional into periodontal pockets once every 3 months.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
Terminal half-life 16-18 hours; prolonged to 24-48 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Primarily renal (60-70% unchanged), biliary/fecal (10-15%) as active drug and metabolites; remainder metabolized.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic